IMR Press / FBE / Volume 2 / Issue 4 / DOI: 10.2741/E206

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Roles of protein kinase B/Akt in lung cancer

Show Less
1 Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
2 Center for Developmental and Therapeutics, Seattle Children`s Research Institute, Seattle, Washington 98101, USA
3 Laboratory of Toxicology, College of Veterinary Medicine
4 Department of Nano Fusion Technology, Graduate School of Convergence Science and Technology Seoul National University, Seoul 151-742, Korea
5 National Institute of Food and Drug Safety, Seoul 122-704, Korea
Front. Biosci. (Elite Ed) 2010, 2(4), 1472–1484;
Published: 1 June 2010

Lung cancer is the leading cause of cancer-related death worldwide and has frequently been associated with over-activated protein kinase B (PKB)/Akt. Akt is a serine/threonine protein kinase that plays an important role in cell growth, proliferation, and survival. Many lines of evidence point to the contribution of deregulated Akt in development or progression of lung cancer. In addition, recent studies have demonstrated that cancer cells defend themselves from therapeutic treatment through activation of pro-survival signals, including the Akt pathway. In this review, we described the way in which the Akt pathway is activated in development and progression of lung cancer, and the way in which deregulated Akt plays a significant role in lung tumorigenesis and resistance to chemo- or radiotherapy. In this review, we also discussed the potential of the Akt pathway as a target of lung cancer therapy.

Back to top